Bio-Rad Laboratories announced the launch of four new Droplet Digital™ PCR (ddPCR) platforms, significantly expanding its genomics research and applied science market presence. These newly introduced instruments include Bio-Rad’s QX Continuum™ ddPCR system along with the QX700™ series of ddPCR platforms.
The launch coincides with the recently completed acquisition of digital PCR developer Stilla Technologies, whose QX700 series platforms are now part of Bio-Rad's comprehensive portfolio. The expanded product line, which includes over 400,000 assays, offers a broad range of digital PCR products for life science research and diagnostic applications.
The QX Continuum™ ddPCR system is designed for translational research applications, featuring a qPCR-like workflow with four-color multiplexing. The QX700™ series consists of three new ddPCR instruments tailored for academic research, environmental testing, cell and gene therapy, and biopharma quality control workflows, enabling seven-color multiplexing and processing over 700 samples per day.
These end-to-end solutions provide industry-leading absolute quantification, high precision, and advanced multiplexing capabilities, combined with streamlined and simplified workflows. The integration of Stilla's technology and the new product launches allow Bio-Rad to serve a full spectrum of digital PCR applications and meet evolving customer needs.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.